HTS demands highlight sub-microlitre need
22/08/2005 - The importance of high-throughput screening and human microdosing during clinical trial processes has highlighted an emerging trend in drug R&D that uses smaller and smaller test volumes, helped by sophisticated automation technologies and reagents.
The concept of using nanomolar concentrations represents significant time and cost savings. Using smaller volumes of reagents means that diffusion of compounds can occur more quickly, and this speeds up the time it takes for a reaction to complete.
Despite all the coverage, high throughput screening remains a new method even for the pharmaceutical industry. The first commercial 384-well plates were introduced in 1992 and the first commercial 1536-well plates arrived in 1997.
